Skip to content
PresyoGamot
Menu

Medroxyprogesterone price in the Philippines

Quick answer

The DOH reference price for medroxyprogesterone 10 mg tablet is ₱65.00 per tablet (median, June 2024 index); drugstore prices are usually higher. FDA Philippines lists 25 registered medroxyprogesterone products (checked 2026-11-05): 3 as unbranded generics and 22 under 19 brand names. It is a prescription (Rx) medicine. Ask the pharmacist for the unbranded generic of the same strength.

FDA-registered: 25 products19 brandsPrescription (Rx)

Government reference price

Medroxyprogesterone 10 mg Tablet₱65.00DOH reference, median per tablet

At the DOH median, 30 tablets cost about ₱1,950.00, a month at one a day.

DPRI range, DOH DPRI June 2024. What public hospitals pay; drugstore prices are usually higher.

DOH reference prices

Medroxyprogesterone: DOH reference prices

2 items in the DOH index; the lowest median is ₱47.67 for medroxyprogesterone 150 mg/ml, 1 ml suspension for injection vial.

Medroxyprogesterone: DOH reference prices
ItemLowest (₱)Median (₱)Highest (₱)Type
Medroxyprogesterone 10 mg Tablet₱55.00₱65.00₱82.02DPRI range
Medroxyprogesterone 150 mg/mL, 1 mL Suspension for Injection Vial₱37.44₱47.67₱57.90DPRI range

Source: DOH Drug Price Reference Index, June 2024. Prices per unit (tablet, vial, bottle) in pesos, VAT included unless the medicine is VAT-exempt. Hospitals and other facilities may price up to 6.8% above the index, except MWP items.

Strengths

Medroxyprogesterone by strength

Medroxyprogesterone is listed here in 2 strengths; 2 of them (5 mg, 10 mg) have FDA-registered products in the Philippines.

Medroxyprogesterone by strength
StrengthDOH median (₱)FDA products
Medroxyprogesterone 5 mg–2
Medroxyprogesterone 10 mg₱65.006

Sources: FDA Philippines registry (2026-11-05), DOH DPRI June 2024.

About medroxyprogesterone

Used for

Medroxyprogesterone acetate is a progestin hormone. The US FDA label for medroxyprogesterone acetate tablets lists:

  • missed periods (secondary amenorrhea)
  • abnormal bleeding from the womb due to hormone imbalance, when fibroids or cancer are not the cause
  • protecting the womb lining from overgrowth (endometrial hyperplasia) in women after menopause who still have a uterus and take estrogen tablets

How it works

When the body has enough estrogen, medroxyprogesterone changes the womb lining from its growing phase to its secretory phase.

How to take it and usual dose

For missed periods, the label gives 5 or 10 mg a day for 5 to 10 days. For abnormal bleeding, the same dose starts on day 16 or 21 of the cycle. Bleeding usually follows within 3 to 7 days of stopping. With daily estrogen after menopause, 5 or 10 mg is taken for 12 to 14 days each month. Your doctor decides the dose.

Do not use if

  • you have vaginal bleeding that has not been checked by a doctor
  • you have or had breast cancer, or a hormone-sensitive cancer
  • you have or had blood clots, a stroke or a heart attack
  • you have liver disease
  • you are or may be pregnant
  • you have had a severe allergic reaction to medroxyprogesterone

The US label carries a boxed warning: estrogen plus progestin therapy raised the risk of clots, stroke, heart attack, breast cancer and probable dementia.

Common side effects

Reported effects with the tablets alone include:

  • irregular bleeding or spotting, and changes in periods
  • breast tenderness
  • nausea
  • headache, dizziness and sleep problems
  • low mood
  • acne or weight change

Blood clots have also been reported. Get urgent help if a clot, stroke or heart attack is suspected.

Source: US FDA label (DailyMed), 2026-01-01. A summary of the official label, not medical advice: your doctor or pharmacist knows your case.

Registered products

Registered medroxyprogesterone products

FDA Philippines lists 25 registrations under 20 brand names (one row is unbranded generics).

Registered medroxyprogesterone products
BrandStrength and formClassManufacturerReg.
DB-1010 mg TabletRxUnicure Remedies Pvt. Ltd. (India)1
DB-55 mg TabletRxUnicure Remedies Pvt. Ltd. (India)1
Depo-Gestin150 mg/mL Suspension for Injection (IM); 50 mg/mL Suspension For Injection(IM)RxA.N.B. Laboratories Company Limited (Thailand)2
Depo-Queen150 mg/mL Suspension for Injection (IM)RxHansel Pharmaceuticals (Pvt.) Ltd. (Pakistan)1
Depofemme150 mg/mL Suspension For Injection (I.M.)RxPT Triyasa Nagamas Farma (Indonesia)1
Depotrust50 mg/mL Sterile Suspension for I.M. Injection; 50mg/mL Suspension For Injection (I.M.)RxUmeda Co., Ltd. (Thailand)2
Dimple150 mg/ mL Suspension for Injection (IM)RxMylan Laboratories Ltd. (India)1
Famy-Depo150 mg/mL Suspension for Injection (IM)RxSenador Laboratories Private Limited (India)1
Show 12 more brands

Registered medroxyprogesterone products, continued

Registered medroxyprogesterone products, continued
BrandStrength and formClassManufacturerReg.
Feroxyron5 mg TabletRxUnicure Remedies Pvt. Ltd. (India)1
Lyndavel150 mg/mL Suspension For Injection (I.M.)RxUmeda Co., Ltd. (Thailand)1
Medrofix10 mg TabletRxUnicure Remedies Pvt. Ltd. (India)1
Medroxcure10 mg TabletRxUnicure Remedies Pvt. Ltd. (India)1
Medroxin150mg/mL Suspension for Injection (IM)RxPT Harsen Laboratories (Indonesia)1
Medwin150 mg/mL Suspension For Injection (I.M); 150 mg/mL Suspension for Injection (IM, Pre-Filled Syringe)RxEugia Pharma Specialities Limited (India)2
Profemme10 mg TabletRxSteril-Gene Life Sciences (P) Ltd. (India)1
Protec150 mg/mL Suspension for Injection (I.M.)RxA.N.B. Laboratories Company Limited (Thailand)1
Provera10 mg TabletRxPfizer Italia S.R.L. (Italy)1
Provestin50 mg/mL (150mg/3mL) Suspension for Injection (1.M.)RxL.B.S. Laboratory Ltd. (Thailand)1
Xygyn10 mg TabletRxUnicure Remedies Pvt. Ltd. (India)1
No brand (generic)150 mg/mL Suspension For Injection (I.M); 150 mg/mL Suspension For Injection (I.M.); 150 mg/mL Suspension For Injection (IM)RxEugia Pharma Specialities Limited (India) +1 more3

Source: FDA Philippines product registry, checked 2026-11-05. Look up any registration number at verification.fda.gov.ph.

Official leaflets

The package insert (PI) and patient leaflet (PIL) filed with FDA Philippines. Doses, side effects and warnings are there, written by the maker and approved by FDA.

Paying less for medroxyprogesterone

  • Ask for the generic

    Prescriptions are written in generic names, and the pharmacist must tell you every brand of that generic and its price. How it works

  • Senior or PWD card

    20% off plus no VAT on your own medicines, with ID and prescription. What to bring

Questions people ask

Do I need a prescription for medroxyprogesterone in the Philippines?

FDA Philippines classifies medroxyprogesterone as a prescription (Rx) medicine. A pharmacist may dispense it only against a valid prescription (Pharmacy Act, RA 10918).

Is there a generic medroxyprogesterone registered in the Philippines?

FDA Philippines lists 25 registered medroxyprogesterone products (checked 2026-11-05): 3 sold under the generic name only and 22 under 19 brand names. Ask the pharmacist for the unbranded generic: same ingredient and strength.

How much does medroxyprogesterone cost in the Philippines?

The DOH Drug Price Reference Index, June 2024 edition, lists medroxyprogesterone 10 mg tablet at a median of ₱65.00 (range ₱55.00 to ₱82.02). That is what public hospitals pay; drugstore prices are usually higher.

Where can I buy medroxyprogesterone legally?

From an FDA-licensed drugstore or botika; the licence to operate (LTO) should be displayed in the store. Bring your prescription. Check that the box carries a DR- registration number, and be careful with online sellers that are not licensed pharmacies.

Is medroxyprogesterone over the counter in the Philippines?

No. FDA Philippines lists all registered products, including 5 mg and 10 mg tablets and the 50 mg/mL and 150 mg/mL injections, as prescription (Rx) drugs.

What is medroxyprogesterone 10 mg for?

In the US label, 10 mg a day for 5 to 10 days is one dose for missed periods and for abnormal bleeding from hormone imbalance.

Data: FDA Philippines registry (checked 2026-11-05), DOH Drug Price Reference Index (June 2024). Sources and method.